Abstract
This chapter presents perspectives from the pharmaceutical industry concerning the development of orphan drugs. This includes outlining orphan drug development in biotechnology, the various factors necessary for commercializing orphan drug candidates, phases and trials of clinical development and factors which may affect commercialization of a product. The chapter concludes with implications for patients and families.
The secret of business is to know something that nobody else knows
ARISTOTLE ONASSIS
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barton NW, Brady RO. Macrophage-targeted glucocerebrosidase: a therapeutically effective enzyme replacement product for Gaucher disease. In: Lauwers A, Scharpè S, ediors. Pharmaceutical Enzymes. Marcel Dekker, New York; 1997; 261–83.
Code of Federal Regulations. “Applications for FDA approval to market a new drug”, title 21, code of federal regulations, part 314.50, available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.50. (2012a). Accessed: 4/9/2013.
Code of Federal Regulations. “Adequate and well-controlled studies”, Title 21: Code of Federal Regulations, Part 314.126, available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126. (2012b). Accessed 4/9/2013.
Code of Federal Regulations. “Content and format of an application”, Title 21, Code of Federal Regulations, Part 314.50H, available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.50. (2012c). Accessed 4/9/2013.
Heemstra HE, de Vrueh RL, van Weely S, Buller HA, Leufkens HG. Predictors of orphan drug approval in the European Union. Eur J Clin Pharmacol. 2008;64(5):545–545.
Heemstra HE, van Weely S, Buller HA, Leufkens HG, de Vrueh RL. Translation of rare disease research into orphan drug development: disease matters. Drug Discov Today. 2009;14(23–24):1166–73.
Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101.
Shire HGT (2013) Rare disease impact report, April 2013, [online], www.rarediseaseimpact.com. Last Accessed 8 Apr 2013.
Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR. Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Pediatrics. 2010;126:101–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Grégoire, S., Barton, N., Whiteman, D. (2014). Industry Perspectives on Orphan Drug Development. In: Bali, R., Bos, L., Gibbons, M., Ibell, S. (eds) Rare Diseases in the Age of Health 2.0. Communications in Medical and Care Compunetics, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38643-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-38643-5_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-38642-8
Online ISBN: 978-3-642-38643-5
eBook Packages: EngineeringEngineering (R0)